宫颈黏液腺癌的诊治进展

doi:10.12280/gjfckx.20230139

摘要/Abstract

摘要：

宫颈黏液腺癌是宫颈恶性肿瘤中一种罕见的、特殊的组织学类型，其分类主要有宫颈胃型腺癌、宫颈肠型腺癌和宫颈原发印戒细胞型腺癌等。由于宫颈黏液腺癌的发病机制与人乳头瘤病毒（human papilloma virus，HPV）感染之间的不确定性，因此难以通过常规宫颈癌筛查加以提示。同时，宫颈黏液腺癌的病因及发病机制均不明确，且缺乏典型临床表现及早期诊断方法，临床病理特征及治疗与宫颈普通腺癌有所不同，导致患者易错过最佳治疗时机，因此宫颈黏液腺癌较宫颈普通型腺癌的预后差。近年来，由于对HPV疫苗的普及，宫颈黏液腺癌相对发病率较前略有升高，关于宫颈黏液腺癌的研究越来越受到重视，综述宫颈黏液腺癌的国内外相关研究，探讨宫颈黏液腺癌的相关发病机制、临床特征及治疗，以期为宫颈黏液腺癌的临床诊治提供参考。

关键词: 宫颈肿瘤, 腺癌, 黏液, 宫颈胃型腺癌, 宫颈肠型腺癌, 宫颈原发印戒细胞型腺癌, 诊断, 治疗, 预后

Abstract:

Cervical mucinous adenocarcinoma is a rare and special histological type of cervical malignant tumor, which mainly includes adenocarcinoma of the cervix gastric type, adenocarcinoma of the cervix and intestines, and primary cervical signet-ring cell carcinoma. Due to the uncertainty between the pathogenesis of cervical mucinous adenocarcinoma and human papillomavirus (HPV) infection makes it difficult to be suggested by routine cervical cancer screening. Meanwhile, the etiology and pathogenesis of cervical mucinous adenocarcinoma are not clear, and there is a lack of typical clinical manifestations and early diagnosis methods, and the clinicopathological features and treatment are different from those of cervical common adenocarcinoma, resulting in patients being prone to miss the best treatment time, so the prognosis of cervical mucinous adenocarcinoma is worse than that of cervical common adenocarcinoma. In recent years, due to the popularization of HPV vaccine, the relative incidence of cervical mucinous adenocarcinoma has slightly increased compared with before, and the research on cervical mucinous adenocarcinoma has received more and more attention. The relevant research on cervical mucinous adenocarcinoma at home and abroad is reviewed, and the relevant pathogenesis, clinical features and treatment of cervical mucinous adenocarcinoma are discussed, in order to provide a reference for the clinical diagnosis and treatment of cervical mucinous adenocarcinoma.

Key words: Uterine cervical neoplasms, Adenocarcinoma, mucinous, Adenocarcinoma of the cervix gastric type, Adenocarcinoma of the cervix and intestines, Primary cervical signet-ring cell carcinoma, Diagnosis, Therapy, Prognosis

宋小幸, 田婷婷, 史惠蓉, 贾艳艳. 宫颈黏液腺癌的诊治进展[J]. 国际妇产科学杂志, 2023, 50(4): 366-371.

SONG Xiao-xing, TIAN Ting-ting, SHI Hui-rong, JIA Yan-yan. Advances in Diagnosis and Treatment of Cervical Mucinous Adenocarcinoma[J]. Journal of International Obstetrics and Gynecology, 2023, 50(4): 366-371.

参考文献 38

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Liu P, Ji M, Kong Y, et al. Comparison of survival outcomes between squamous cell carcinoma and adenocarcinoma/adenosquamous carcinoma of the cervix after radical radiotherapy and chemotherapy[J]. BMC Cancer, 2022, 22(1):326. doi: 10.1186/s12885-022-09401-x. doi: 10.1186/s12885-022-09401-x pmid: 35337279
[3]	Shi H, Shao Y, Zhang H, et al. Independent validation of distinct clinicopathological features and prognosis among usual-type, mucinous-type and gastric-type endocervical adenocarcinoma categorised by new WHO classification(2020)[J]. Pathology, 2022, 54(5):555-562. doi: 10.1016/j.pathol.2021.12.301. doi: 10.1016/j.pathol.2021.12.301
[4]	Stoler M, Bergeron C, Colgan TJ. WHO classification of tumours of female reproductive organs[R]. International Agency for Research on Cancer Lyon, 2014:169-189.
[5]	Pirog EC, Lloveras B, Molijn A, et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases[J]. Mod Pathol, 2014, 27(12):1559-1567. doi: 10.1038/modpathol.2014.55. doi: 10.1038/modpathol.2014.55
[6]	Mikami Y. Gastric-type mucinous carcinoma of the cervix and its precursors-historical overview[J]. Histopathology, 2020, 76(1):102-111. doi: 10.1111/his.13993. doi: 10.1111/his.13993
[7]	李晶, 孔繁斗, 汪俊颖. Peutz-Jeghers综合征合并多发妇科肿瘤一例[J]. 国际妇产科学杂志, 2022, 49(4):403-406,419. doi: 10.12280/gjfckx.20211164. doi: 10.12280/gjfckx.20211164
[8]	Watanabe T, Soeda S, Endo Y, et al. Rare Hereditary Gynecological Cancer Syndromes[J]. Int J Mol Sci, 2022, 23(3):1563. doi: 10.3390/ijms23031563. doi: 10.3390/ijms23031563
[9]	Asaka S, Nakajima T, Ida K, et al. Clinicopathological and prognostic significance of immunophenotypic characterization of endocervical adenocarcinoma using CLDN18, CDH17, and PAX8 in association with HPV status[J]. Virchows Arch, 2022, 480(2):269-280. doi: 10.1007/s00428-021-03207-1. doi: 10.1007/s00428-021-03207-1
[10]	Howitt BE, Herfs M, Brister K, et al. Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women[J]. Am J Surg Pathol, 2013, 37(5):625-633. doi: 10.1097/PAS.0b013e318285be00. doi: 10.1097/PAS.0b013e318285be00 pmid: 23552379
[11]	Asaka S, Nakajima T, Kugo K, et al. Immunophenotype analysis using CLDN18, CDH17, and PAX8 for the subcategorization of endocervical adenocarcinomas in situ: gastric-type, intestinal-type, gastrointestinal-type, and Müllerian-type[J]. Virchows Arch, 2020, 476(4):499-510. doi.org/10.1007/s00428-019-02739-x. doi: doi.org/10.1007/s00428-019-02739-x
[12]	Li S, Gan F, Luo M, et al. A Rare Case of Primary Signet-Ring Cell Cervical Carcinoma: Early Stage with Independent Bilateral Ovarian Metastases[J]. Onco Targets Ther, 2021, 14:2101-2107. doi.org/10.2147/OTT.S300424. doi: doi.org/10.2147/OTT.S300424
[13]	Kawai S, Torii Y, Kukimoto I, et al. A case of primary signet-ring cell carcinoma of the cervix containing full genome of human papillomavirus 16[J]. Indian J Pathol Microbiol, 2019, 62(1):146-148. doi: 10.4103/IJPM.IJPM_507_17. doi: 10.4103/IJPM.IJPM_507_17
[14]	Yoon A, Kim SH, Kim HJ, et al. Primary signet ring cell carcinoma of the uterine cervix: A case report[J]. Korean J Obstet Gynecol, 2011, 54(9):570-573. doi: 10.5468/kjog.2011.54.9.570. doi: 10.5468/kjog.2011.54.9.570
[15]	Muresan G, Szabo KE, Marian C, et al. Intestinal type in situ adenocarcinoma of the cervix as a precursor of cervical signet ring cell adenocarcinoma[J]. Rev Rom Med Labor, 2012, 20(3):87-92.
[16]	Kerwin CM, Markese M, Moroney MR, et al. Adenocarcinoma of the uterine cervix, gastric-type (GAS): a review of the literature focused on pathology and multimodality imaging[J]. Abdom Radiol (NY), 2023, 48(2):713-723. doi: 10.1007/s00261-022-03724-w. doi: 10.1007/s00261-022-03724-w
[17]	Schwock J, Starova B, Khan ZF, et al. Cytomorphologic Features of Gastric-Type Endocervical Adenocarcinoma in Liquid-Based Preparations[J]. Acta Cytol, 2021, 65(1):56-66. doi: 10.1159/000511003. doi: 10.1159/000511003 pmid: 33152741
[18]	Li G, Jiang W, Gui S, et al. Minimal deviation adenocarcinoma of the uterine cervix[J]. Int J Gynaecol Obstet, 2010, 110(2):89-92. doi: 10.1016/j.ijgo.2010.03.016. doi: 10.1016/j.ijgo.2010.03.016 pmid: 20451906
[19]	唐雪珍, 欧阳春艳, 黄燕红, 等. 宫颈胃型腺癌超声表现1例[J]. 中华超声影像学杂志, 2022, 31(5):448-449. doi: 10.3760/cma.j.cn131148-20210930-00695. doi: 10.3760/cma.j.cn131148-20210930-00695
[20]	Park SB, Moon MH, Hong SR, et al. Adenoma malignum of the uterine cervix: ultrasonographic findings in 11 patients[J]. Ultrasound Obstet Gynecol, 2011, 38(6):716-721. doi: 10.1002/uog.9078. doi: 10.1002/uog.9078 pmid: 21919103
[21]	Ohya A, Kobara H, Miyamoto T, et al. Usefulness of the ′cosmos pattern′ for differentiating between cervical gastric-type mucin-positive lesions and other benign cervical cystic lesions in magnetic resonance images[J]. J Obstet Gynaecol Res, 2021, 47(2):745-756. doi: 10.1111/jog.14602. doi: 10.1111/jog.14602
[22]	Ehmann S, Sassine D, Straubhar AM, et al. Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers[J]. Gynecol Oncol, 2022, 167(3):458-466. doi: 10.1016/j.ygyno.2022.10.003. doi: 10.1016/j.ygyno.2022.10.003 pmid: 36253302
[23]	Liu S, Guo Y, Li B, et al. Analysis of Clinicopathological Features of Cervical Mucinous Adenocarcinoma with a Solitary Ovarian Metastatic Mass as the First Manifestation[J]. Cancer Manag Res, 2020, 12:8965-8973. doi: 10.2147/CMAR.S270675. doi: 10.2147/CMAR.S270675 pmid: 33061592
[24]	Kojima A, Shimada M, Mikami Y, et al. Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group[J]. Int J Gynecol Cancer, 2018, 28(1):99-106. doi: 10.1097/IGC.0000000000001145. doi: 10.1097/IGC.0000000000001145 pmid: 29206664
[25]	Nishio S, Mikami Y, Tokunaga H, et al. Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional study[J]. Gynecol Oncol, 2019, 153(1):13-19. doi: 10.1016/j.ygyno.2019.01.022. doi: S0090-8258(19)30063-0 pmid: 30709650
[26]	Yang J, Yang J, Cao D, et al. Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery[J]. J Gynecol Oncol, 2020, 31(2):e16. doi: 10.3802/jgo.2020.31.e16. doi: 10.3802/jgo.2020.31.e16
[27]	Lu S, Shi J, Zhang X, et al. Comprehensive genomic profiling and prognostic analysis of cervical gastric-type mucinous adenocarcinoma[J]. Virchows Arch, 2021, 479(5):893-903. doi: 10.1007/s00428-021-03080-y. doi: 10.1007/s00428-021-03080-y
[28]	Hodgson A, Howitt BE, Park KJ, et al. Genomic Characterization of HPV-related and Gastric-type Endocervical Adenocarcinoma: Correlation With Subtype and Clinical Behavior[J]. Int J Gynecol Pathol, 2020, 39(6):578-586. doi: 10.1097/PGP.0000000000000665. doi: 10.1097/PGP.0000000000000665
[29]	Nakamura A, Yamaguchi K, Minamiguchi S, et al. Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification[J]. Med Mol Morphol, 2019, 52(1):52-59. doi: 10.1007/s00795-018-0202-2. doi: 10.1007/s00795-018-0202-2 pmid: 29992451
[30]	Stolnicu S, Barsan I, Hoang L, et al. Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas[J]. Am J Surg Pathol, 2018, 42(8):989-1000. doi: 10.1097/PAS.0000000000001090. doi: 10.1097/PAS.0000000000001090 pmid: 29851704
[31]	Garg S, Nagaria TS, Clarke B, et al. Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing[J]. Mod Pathol, 2019, 32(12):1823-1833. doi: 10.1038/s41379-019-0305-x. doi: 10.1038/s41379-019-0305-x
[32]	Liu Y, Zhao R, Fang S, et al. Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways[J]. Fundam Clin Pharmacol, 2021, 35(1):156-164. doi: 10.1111/fcp.12574. doi: 10.1111/fcp.12574
[33]	Liao X, Xia X, Su W, et al. Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma[J]. Gynecol Oncol, 2022, 165(1):105-113. doi: 10.1016/j.ygyno.2022.01.036. doi: 10.1016/j.ygyno.2022.01.036 pmid: 35151492
[34]	Karamurzin YS, Kiyokawa T, Parkash V, et al. Gastric-type Endocervical Adenocarcinoma: An Aggressive Tumor With Unusual Metastatic Patterns and Poor Prognosis[J]. Am J Surg Pathol, 2015, 39(11):1449-1457. doi: 10.1097/PAS.0000000000000532. doi: 10.1097/PAS.0000000000000532 pmid: 26457350
[35]	Chen L, Lucas E, Zhang X, et al. Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance[J]. Histopathology, 2022, 80(2):338-347. doi: 10.1111/his.14552. doi: 10.1111/his.14552
[36]	刘萍, 李淼, 赵东奇, 等. 宫颈原发性印戒细胞癌临床特点分析[J]. 世界最新医学信息文摘, 2021, 21(102):522-524. doi: 10.3969/j.issn.1671-3141.2021.102.178. doi: 10.3969/j.issn.1671-3141.2021.102.178
[37]	李西梅, 宋杰. 39例宫颈粘液腺癌的临床分析[D]. 长春: 吉林大学, 2021.
[38]	Giordano G, Pizzi S, Berretta R, et al. A new case of primary signet-ring cell carcinoma of the cervix with prominent endometrial and myometrial involvement: Immunohistochemical and molecular studies and review of the literature[J]. World J Surg Oncol, 2012, 10:7. doi: 10.1186/1477-7819-10-7. doi: 10.1186/1477-7819-10-7 pmid: 22236794